PALO ALTO, Calif.--(BUSINESS WIRE)--Contract manufacturing of biopharmaceuticals has moved beyond being a function of “available capacity” and “cost” to a strategic option offering flexibility, quicker time to market, and lower scale-up costs. The market will continue to witness double-digit growth as the current demand is largely driven by first-generation products – rh protein therapeutics and monoclonal antibodies (MAbs) targeted for cancer.
